The One Drug That Stops Babies From Going Blind Just Got Recalled
Pfizer just recalled the only FDA-approved drug that can stop syphilis from passing to unborn babies, and there's no real substitute for pregnant patients. With congenital syphilis already at its highest levels in decades, the timing couldn't be worse.
Imagine there's only one fire extinguisher in the building, and someone just pulled it off the wall for inspection. That's essentially what happened on July 10, when Pfizer issued a voluntary recall of Bicillin L-A, the lone FDA-approved penicillin injection used to treat syphilis in pregnant patients. The timing could not be worse.
Congenital syphilis (syphilis passed from mother to baby during pregnancy) is already surging across the United States. Nearly 4,000 newborns were diagnosed with it in 2024, up nearly 700% since 2015. About 5–10% of those cases end in stillbirth or infant death. The rest can mean lifelong disability.
And now, the only drug proven to stop that from happening is disappearing from pharmacy shelves.
Floating Particles, Massive Consequences
The recall traces back to something deceptively simple: tiny floating particles spotted inside prefilled syringes. The company classified the health risk as "medium," and no adverse events have been reported from the affected lots.
But the scope of the recall is staggering. It covers both the 1.2 million-unit and 2.4 million-unit syringe presentations of Bicillin L-A, spanning lots distributed from December 2023 through June 2025. That's roughly 18 months of product pulled from circulation. Health departments across the country have told clinics to quarantine any matching stock immediately.
Pfizer says corrective measures are underway. But "underway" doesn't help the pregnant patient sitting in an OB clinic right now.
Why There's No Plan B for Pregnant Patients
For most adults with syphilis, there's a perfectly fine backup: doxycycline, an oral antibiotic that costs pennies and sits in medicine cabinets everywhere. Men and non-pregnant women can take it for 14 to 28 days depending on the stage of infection.
Pregnant patients can't.
Doxycycline is classified as an FDA Pregnancy Category D drug, meaning it poses real risks to a developing fetus. Erythromycin and azithromycin don't reliably cross the placenta well enough to treat the baby. Ceftriaxone lacks sufficient data. The CDC is unambiguous on this point:
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
"No proven alternatives to penicillin are available for treatment of syphilis during pregnancy."
That's not a preference. It's not a guideline committee being conservative. It's a biological reality. Benzathine penicillin G is the only antibiotic documented to clear syphilis in both the mother and the fetus. Without it, you're essentially watching a preventable tragedy unfold in slow motion.
One Company, One Drug, Zero Margin for Error
Here's the part that should make your blood boil: Pfizer is the only FDA-approved domestic manufacturer of this drug. Not one of a few. The only one. For a medication that treats a disease infecting thousands of pregnant women every year, the entire U.S. supply chain runs through a single company and a single production line.
It's like building a bridge with one support cable and then acting surprised when it snaps.
The FDA has tried to patch the gap by authorizing temporary imports. Extencilline, made by Laboratories Delbert in Italy and distributed by Provepharm, is one option. Lentocilin, manufactured by Laboratories Atral in Portugal and distributed by Mark Cuban's Cost Plus Drug Company, is another. Both are considered equivalent to Bicillin L-A by the CDC.
But "temporary" is doing a lot of heavy lifting in that sentence. Reports indicate that both imported products have faced their own availability problems, with some jurisdictions finding them limited or unavailable by early 2026. CDC estimates place the supply recovery timeline for adult syringe presentations of Bicillin L-A at Q4 2027.
The Rationing Has Already Started
Public health agencies aren't waiting around. A triage system is now in effect across much of the country, and the rules are stark:
Priority access to remaining Bicillin goes to pregnant patients and infants. Everyone else gets doxycycline.
Pfizer has implemented an allocation process requiring providers to submit per-patient medical request forms to obtain the drug. The company is prioritizing facilities treating patients at highest risk for congenital syphilis. State health departments are maintaining centralized inventories and redistributing doses to where they're needed most.
Clinicians are also being coached to stretch every vial. Treat at the first positive test rather than waiting for confirmatory results. Stage the infection carefully, because earlier stages require fewer doses. Coordinate with local health departments so no dose sits idle in one clinic while a pregnant patient goes without at another.
These are smart, necessary moves. They're also the kind of moves you make when the system has already failed.
A Crisis Built on Top of a Crisis
The cruelest irony of this recall is that congenital syphilis was already a public health emergency before the drug supply collapsed. Cases have risen for 12 consecutive years. Maternal syphilis rates jumped 28% between 2022 and 2024 alone, with especially steep increases among American Indian/Alaska Native mothers (up 52%) and Black mothers (up 30%).
Nearly 90% of congenital syphilis cases in 2022 involved missed opportunities for testing or treatment during pregnancy. More than a third of affected babies were born to mothers who received no prenatal care at all. The barriers are familiar: lack of insurance, unstable housing, substance use, fear of the healthcare system.
Adult syphilis rates actually fell 22% in 2024 compared to the prior year. But congenital cases kept climbing. The disease is retreating among adults while still advancing on the most vulnerable patients, the ones who literally cannot speak for themselves.
What Comes Next
The immediate playbook is clear: conserve every available dose of benzathine penicillin for pregnant patients and newborns, substitute doxycycline for everyone else, and keep pushing for imported alternatives. Clinics should be checking their inventory against the recall lot numbers right now.
But the longer conversation is about something bigger. A country that spends more on healthcare than any other nation on Earth shouldn't be rationing a drug that Alexander Fleming's discovery made possible nearly a century ago. The single-source dependency on Pfizer for an irreplaceable maternal medication isn't just a supply chain weakness; it's a policy failure with infant lives on the line.
Congenital syphilis is, by every expert's account, "totally preventable." The word "preventable" hits differently when the only prevention tool just got pulled from the shelf.
5 min read
Sarepta's Worst Week: Two Deaths, a Black Box, and 500 Pink Slips
Sarepta's Duchenne gene therapy Elevidys just got the FDA's most severe safety warning after fatal liver failures, while the company slashes 36% of its workforce and pivots away from gene therapy entirely. It's a brutal week that raises big questions about the future of the entire field.
